U.S. market Closed. Opens in 8 hours 8 minutes

KRYS | Krystal Biotech, Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for KRYS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is very poor, Growth is very bad and Health is very strong.

Valuation (24%)

Company Industry
P/E Ratio (TTM) 87.34 -17.03
PEG Ratio (TTM) -1.70 -5.07
P/S Ratio (TTM) 18.97 47.59
P/B Ratio (TTM) 5.16 27.99
P/FCF Ratio (TTM) 78.90 -4.65
Price to 5YR AVG Earnings Ratio -71.53 -5.55
Price to 5YR AVG FCF Ratio -52.48 -12.72

Profitability (40%)

Company Industry
ROA (TTM) 5.33% -16.83%
ROE (TTM) 6.34% 27.79%
Net Profit Margin (TTM) 21.69% -828.54%
ROIC 5YR AVG -34.02% -21.97%

Growth (33%)

4QTR AVG 3YR AVG 5YR AVG
EPS 399.09% -49.75% -23.47%
Revenue 118.64% -33.33% -20.00%
Net Income 366.62% -86.70% -50.70%
Cash Flow 442.88% -73.77% -63.88%

Health (74%)

Company Industry
Current Ratio (TTM) 7.97 5.78
Quick Ratio (TTM) 7.76 5.56
D/E Ratio (TTM) 0.00 0.94
Interest Coverage (TTM) N/A -7.39
Piotroski F-Score 6 5
Altman Z-Score 29.39 12.93
LTL to 5YR AVG FCF -0.08 0.12
Shares Outstanding Growth 5YR AVG 19.92% 42.84%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙